Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression
Open accessThe DOI matches its Crossref record; 64 of the 65 references it cites were found in a registry or an index.
Abstract
Psilocybin shows efficacy to alleviate depression in human clinical trials for six or more months after only one or two treatments. Another hallucinogenic drug, esketamine, has recently been U.S. Food and Drug Administration (FDA)-approved as a rapid-acting antidepressant. The mechanistic basis for the antidepressant effects of psilocybin and ketamine appear to be conserved. The efficacy of these two medications has not, however, been directly compared either clinically or preclinically. Further, whether or not a profound subjective existential experience is necessary for psilocybin to have antidepressant effects is unknown. To address these questions, we tested psilocybin, lysergic acid diethylamide (LSD), and ketamine in a rat model for depression. As in humans, a single administration of psilocybin or LSD produced persistent antidepressant-like effects in our model. In contrast, ketamine produced only a transient antidepressant-like effect. Our results indicate that classic psychedelics may have therapeutic efficacy that is more persistent than that of ketamine, and also suggest that a subjective existential experience may not be necessary for therapeutic effects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ketamine's effects on structural plasticity appear to last for approximately a week (150) while psilocybin's effects seem to be more durable lasting for at least a month (151, 152)”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [151]
In the citing paper
“This may explain why they have demonstrated efficacy in many preclinical rodent behavioral tests involving PFC circuitry including the forced swim test and fear extinction learning (151, 194–197).”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [151]
In the citing paper
“the mood-elevating properties of psilocybin seem to last significantly longer”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [151]
Citations
Cites
A Simple Practice Guide for Dose Conversion between Animals and Human
Nair, A., & Jacob, S. (2016) · Journal of Basic and Clinical Pharmacy · doi:10.4103/0976-0105.177703 · Cited by 6,174
Depression: a new animal model sensitive to antidepressant treatments
PORSOLT, R. D., LE PICHON, M., & JALFRE, M. (1977) · Nature · doi:10.1038/266730a0 · Cited by 4,451
The use of the elevated plus maze as an assay of anxiety-related behavior in rodents
Walf, A. A., & Frye, C. A. (2007) · Nature Protocols · doi:10.1038/nprot.2007.44 · Cited by 3,035
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970
Using the rat forced swim test to assess antidepressant-like activity in rodents
Slattery, D. A., & Cryan, J. F. (2012) · Nature Protocols · doi:10.1038/nprot.2012.044 · Cited by 903
Research works printed but not linked: 3
- Russell, 2009, The three Rs and the humanity criterion
- Hibicke, M. (2017) Development and Evaluation of an Adolescent Chronic Restraint Stress (ACRS) Protocol to Model Adult Depression in Female Rats. Ph.D. Thesis, Mercer University.
- Sengupta, 2013, The Laboratory Rat: Relating Its Age With Human’s, Int. J. Prev. Med., 4, 624
Cited by
Items 101–200 of 227
Effect of a single psilocybin treatment on Fos protein expression in male rat brain
Funk, D. R., Araujo, J. A., Slassi, M., Lanthier, J., Atkinson, J., Feng, D., Lau, W., Lê, A., & Higgins, G. A. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.01.001 · Cited by 16
Sakai, K., Bradley, E., Zamaria, J. A., Agin-Liebes, G., Kelley, D. P., Fish, A., Martini, V., Ferris, M. C., Morton, E. E., Michalak, E. E., et al. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06585-x · Cited by 17
“Recent preclinical work has raised the possibility that psilocybin’s therapeutic effects may not depend on the acute subjective experience (Hibicke et al. 2020) or 5-HT 2A receptor mechanisms (Hesselgrave et al. 2021; Moliner et al. 2023; Shao et al. 2021).”
The serotonin 1B receptor is required for some of the behavioral effects of psilocybin in mice
Fleury, S., & Nautiyal, K. M. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03387-1 · Cited by 16
Ketamine for Bipolar Depression: Biochemical, Psychotherapeutic, and Psychedelic Approaches
Bennett, R., Yavorsky, C., & BRAVO, G. L. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.867484 · Cited by 16
“One of the challenges in ketamine treatment is that beneficial effect appears to be temporary, especially if one focuses on the “biochemical” effect alone (70, 71).”
BackgroundThe effect of low-dose psilocybin on brain neurotransmission and rat behavior
Bysiek, A., Wojtas, A., Szpręgiel, I., Wawrzczak‐Bargieła, A., Maćkowiak, M., & Gołembiowska, K. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111347 · Cited by 15
Effect of psilocybin on decision-making and motivation in the healthy rat
Roberts, B. F., Zylko, A. L., Waters, C. E., Crowder, J. D., Gibbons, W. J., Sen, A. K., Jones, J. A., & McMurray, M. S. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2022.114262 · Cited by 14
Utility of preclinical models in the study of psilocybin – A comprehensive review
Pedicini, M., & Cordner, Z. A. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105046 · Cited by 15
LSD's rapid antidepressant effects are modulated by 5-HT2B receptors
Bouloufa, A., Delcourte, S., Rovera, R., Delannay, T., Duquet, A., Moulédous, L., Dkhissi‐Benyahya, O., Guiard, B. P., & Haddjeri, N. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118348 · Cited by 14
Adebo, M., Bonnet, M., Laouej, O., Defaix, C., McGowan, J. C., Butlen‐Ducuing, F., David, D. J. P., Poupon, E., Tritschler, L., & Gardier, A. M. (2025) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.70038 · Cited by 14
Matłoka, M., Janowska, S., Gajos‐Draus, A., Ziółkowski, H., Janicka, M., Perko, P., Kamil, K., Pankiewicz, P., Moszczyński-Pętkowski, R., Mach, M., et al. (2022) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2022.102127 · Cited by 14
Meccia, J., Lopez, J., & Bagot, R. C. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06297-0 · Cited by 14
Methylone, a rapid acting entactogen with robust anxiolytic and antidepressant-like activity
Warner‐Schmidt, J. L., Pittenger, C., Stogniew, M., Mandell, B., Olmstead, S. J., & Kelmendi, B. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1041277 · Cited by 14
“In contrast to SAADs like fluoxetine, a feature of RAADs is that they produce more sustainable, longer-lasting effects that do not require daily dosing (22).”
BackgroundBarnett (2024) · doi:10.1089/psymed.2023.0010 · Cited by 13
“140”
Krupp, K. T., Yaeger, J. D. W., Ledesma, L. J., Withanage, M. H. H., Gale, J., Howe, C. B., Allen, T. J., Sathyanesan, M., Newton, S. S., & Summers, C. H. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109949 · Cited by 13
“…behavioral effects of other psychedelics in humans (Carhart-Harris et al., 2021; Griffiths et al., 2016) and rodents (Cameron et al., 2018; Hibicke et al., 2020) assess behavioral changes after the acute behavioral effects (hallucinatory response in humans; HTR response in rodents) of the…”
Preclinical models for evaluating psychedelics in the treatment of major depressive disorder
Alexander, L., Anderson, D., Baxter, L., Claydon, M. D. B., Rucker, J., & Robinson, E. S. J. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17370 · Cited by 13
Clinical and preclinical evidence of psilocybin as antidepressant. A narrative review
Erkizia-Santamaría, I., Horrillo, I., Meana, J. J., & Ortega, J. E. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111249 · Cited by 13
“While some have reported anxiolytic-like effect of psilocybin (Hibicke et al., 2020; Sekssaoui et al., 2024), others have seen anxiogenic-like responses to psilocin administration (Halberstadt et al., 2011).”
Pouyan, N., Sisi, F. Y., Kargar, A., Scheidegger, M., McIntyre, R. S., & Morrow, J. D. (2023) · CNS Drugs · doi:10.1007/s40263-023-01044-1 · Cited by 13
“Hibicke et al. evaluated the long-term effect of LSD ( n = 12 rats) on measures of active and passive coping, namely climbing and immobility [65].”
BackgroundEvaluating the potential for psilocybin as a treatment for post-traumatic stress disorder
Miller, C., & Zoladz, P. R. (2024) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.124.002237 · Cited by 13
van der Gronde, T., Los, L., Herremans, A. H. J., Oosting, R. S., Zorzanelli, R., & Pieters, T. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00412 · Cited by 13
“In a forced swimming test, rats who were dosed with psilocybin developed the coping technique of floating faster than other rats, indicating a window of behavioral flexibility (55).”
MethodPsychedelic-Induced Serotonin 2A Receptor Downregulation Does Not Predict Swim Stress Coping in Mice
Pędzich, B. D., Medrano, M., Buckinx, A., Smolders, I. J., & Bundel, D. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315284 · Cited by 12
Elsilä, L. V., Korhonen, N., Hyytiä, P., & Korpi, E. R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.602770 · Cited by 12
“While many recently published animal studies have concentrated on models of psychiatric disorders (Alper et al., 2018; Cameron et al., 2018; Hibicke et al., 2020), a more general understanding Edited by:”
Backgroundde la Fuente Revenga, M., Zhu, B., Guevara, C. A., Naler, L. B., Saunders, J. M., Zhou, Z., Toneatti, R., Sierra, S., Wolstenholme, J. T., Beardsley, P. M., et al. (2021) · doi:10.1101/2021.02.24.432725 · Cited by 11
Structural basis for psilocybin biosynthesis
Meng, C., Guo, W., Chuan, X., Wen, Y., Zhu, X., Zhang, Q., Liang, Y., Li, H., Xu, S., Qiu, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58239-x · Cited by 11
“Notably, prior studies have reported persistent antidepressant-like effects of psilocybin injected at low doses (1mg/kg) administered to rodent models of depression 46,60 .”
Neurobiology of psilocybin: a comprehensive overview and comparative analysis of experimental models
Adeyinka, D. A., Forsyth, D., Currie, S., & Faraone, N. (2025) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2025.1585367 · Cited by 12
Maltby, C. J., Klein, A. K., Paschen, E., Pinto, J., Dvořák, D., Hedde, J. R., Hanks, A. N., Bianchi, M., & Hughes, Z. A. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811251395386 · Cited by 11
“There have also been mixed reports on the durability of the antidepressant-like effects of psilocybin in rodents (Hibicke et al., 2020; Jefsen et al., 2019; Takaba et al., 2023; Wang et al., 2025).”
CCNP Innovations in Neuropsychopharmacology Award
Gobbi, G. (2024) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.240037 · Cited by 11
“109 Repeated LSD administration elicited antidepressant-like effects in a preclinical model without affecting controls, suggesting that, although the improvements elicited by LSD may be noticeable in disease states, they may not be so remarkable in physiologic states.”
BackgroundFryc, M., Kluzik, D., Czopek, A., Jończyk, J., & Zagórska, A. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110622 · Cited by 10
Palhas, M. L. C., Corne, R., & Mongeau, R. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111533 · Cited by 12
Kramer, H. M., Hibicke, M., Middleton, J. W., Jaster, A. M., Kristensen, J. L., & Nichols, C. D. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02272-3 · Cited by 10
“In the case of ketamine, whose antidepressant-like effects last only about two weeks in both humans [41] and preclinical models [15], the pruning could simply result in a recapitulation of the baseline depressed state.”
Self-citationKim, S., Yang, S., Jung, J., Choi, J., Kang, M., & Joo, J. (2025) · Advanced Science · doi:10.1002/advs.202413786 · Cited by 10
Bryson, N., Alexander, R., Asnis-Alibozek, A. G., & Ehlers, M. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00058 · Cited by 9
A perspective on psychedelic teratogenicity: the utility of zebrafish models
Syed, O. A., Tsang, B., Petranker, R., & Gerlai, R. T. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.08.001 · Cited by 9
Liao, C., O'Farrell, E., Weiner, A. M., Qalieh, Y., Savalia, N. K., Girgenti, M. J., Kwan, K. Y., & Kwan, A. C. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.04.631335 · Cited by 9
“These are followed in subsequent days by changes in behavioral assays such as learned helplessness 8, 9 , forced swim 39 , tail suspension 9 , sucrose preference 40, 41 , fear extinction 42 , and social reward learning 25 .”
García‐Cabrerizo, R., Beruete-Fresnillo, I., Bergas-Cladera, P., & García-Fuster, M. J. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118720 · Cited by 9
Bruno, V., López-Canul, M., Richardson, B., Camarini, R., Marcourakis, T., & Gobbi, G. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251368361 · Cited by 8
Presa, M. H., da Rocha, M. J., Pires, C. S., Ledebuhr, K. N. B., da Costa, G. P., Alves, D. A. C., Bortolatto, C. F., & Brüning, C. A. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00108 · Cited by 8
Ascone, F., Buzzelli, V., Mottarlini, F., Trapano, M. D., Miglioranza, P., Rava, A., Feo, A., Spano, F., Hausman, M., Sugaya, K., et al. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02361-x · Cited by 7
“Beyond their ef fi cacy in anxiety and depression [50 – 52], recent work suggests that psychedelics may also enhance social behavior and cognitive performance, domains disrupted in ASD and FXS [14, 53].”
Fast-acting antidepressant-like effects of ketamine in aged male rats
Hernández‐Hernández, E., Ledesma‐Corvi, S., Jornet-Plaza, J., & García-Fuster, M. J. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00636-y · Cited by 7
“The dose of ketamine was chosen based on previous antidepressant results reported in the literature (e.g., [46–47]) and on our own results [19–20 ].”
MethodSyed, O. A., Petranker, R., & Tsang, B. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106204 · Cited by 7
“The authors, in multiple publications from their group on low-dose LSD (De Gregorio et al., 2016; De Gregorio et al., 2021), explained the dose choices based on previous studies using acute LSD macrodoses of 0.10 – 0.20 mg/kg (Halberstadt et al., 2013; Hibicke et al., 2020).”
InfluentialMalikowska‐Racia, N., Koniewski, M., Gołębiowska, J., & Popik, P. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231205692 · Cited by 7
“Likewise, Hibicke et al. (2020) reported an antidepressant-like effect in the forced swim test in rats 5 weeks following a single LSD (0.15 mg/kg) injection.”
BackgroundMethodInfluentialThe Therapeutic Effects of Classic Psychedelics in Alcohol Use Disorder
Pagni, B. A., Wong, J. M., & Bogenschutz, M. P. (2024) · Current Addiction Reports · doi:10.1007/s40429-024-00581-z · Cited by 7
“For example, psilocybin and LSD reduced learned help-lessness for up to 5 weeks, and psilocybin ameliorated anhedonia-like symptoms 48h post-treatment [19, 32, 41].”
Psilocybin has a narrow therapeutic window as an antidepressant treatment
Seillier, L., Čechová, B., Seillier, A., & Šlamberová, R. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111368 · Cited by 6
Puigseslloses, P., Nadal‐Gratacós, N., Fumàs, B., Modenutti, C. P., Pottie, E., Ortigosa, J., Pablo-Quesada, A., Riera-Colomer, C., Ettcheto, M., Berzosa, X., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03308-2 · Cited by 6
Mechanisms of integration in psychedelic-assisted therapy
Coverdale, N. S., & Cook, D. J. (2023) · Journal of Military Veteran and Family Health · doi:10.3138/jmvfh-2023-0014 · Cited by 6
Effects of psilocybin on uncertain punishment learning
Jacobs, D. S., Bogachuk, A. P., Moing, C. L. L., & Moghaddam, B. (2024) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2024.107954 · Cited by 6
Allen, J., Sun, M., Baker, T. L., Dames, S., Kryskow, P., Christie, B. R., McDonald, S. J., & Shultz, S. R. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03329-x · Cited by 5
Behavioural investigations of psilocybin in non-human animals 1962–2021: A scoping review
Shore, R., Dobson, K., Thomson, N., Barnim, N., Bergman, H. P., Rideout, K., McKeown, S., Olmstead, M. C., Goldie, C. E., & Dumont, É. C. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2025.00364 · Cited by 5
Using Psychedelics in Clinical Practice: Comparing Therapeutic Uses and Potential Harms
Tariq, R. (2022) · Current Clinical Pharmacology · doi:10.2174/2772432817666220321142707 · Cited by 5
Silva, J., Garcia, J., Guimarães, R., Palito, C., Lemos, A. M., Barros, L., & Alves, M. J. (2023) · Springer eBooks · doi:10.1007/978-3-031-18587-8_16 · Cited by 5
Photoswitchable TCB-2 for control of the 5-HT 2A receptor and analysis of biased agonism
Esmaeili, A. J., Montazeri, P., Gomez, J. C., Dumervil, D. J., Nezhad, F. S., & Steinhardt, R. C. (2024) · Chemical Communications · doi:10.1039/d4cc03892d · Cited by 5
Psilocybin-assisted psychotherapy in adults with depression – A literature review
Dorczok, M. C., Mittmann, G., Ettl, T., & Steiner‐Hofbauer, V. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111508 · Cited by 4
Qiao, Y.-X., Dai, W., Yao, Y., Wei, Q.-Q., Yue, C.-X., Yin, Y., Li, Y.-F., & Zhang, L. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111698 · Cited by 4
Davidson, M., Stanciu, G. D., Rabinowitz, J., Untu, I., Dobrin, R., & Tamba, B.-I. (2025) · Dialogues in Clinical Neuroscience · doi:10.1080/19585969.2025.2480566 · Cited by 4
“…facilitate fear extinction in murine models, whether administered as a single high dose or in repeated low doses, while also inducing long-lasting antidepressant-like effects, as evidenced by forced swim tests (catlow et al. 2013; cameron and Olson 2018; cameron et al. 2019; Hibicke et al. 2020).”
de Miranda, A. S., Toscano, E. C. D. B., Venna, V. R., Graeff, F. G., & Teixeira, A. L. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2460674 · Cited by 4
“…of psilocybin relies on activation of serotonin 5-HT2A receptors, these findings support the concept that therapeutic strategies focused on these serotonin receptors may be at least equal to those focused on glutamatergic neurotransmission (proposed mechanism of action of ketamine) in TRD [45].”
InfluentialIs there a place for psychedelics in sports practice?
Portes, M. A. M., Werle, I., & Bertoglio, L. J. (2025) · Acta Neuropsychiatrica · doi:10.1017/neu.2025.13 · Cited by 4
“Several psychedelics have been shown to decrease immobility and increase active behaviours, including swimming and climbing (Cameron et al ., 2018; Hibicke et al ., 2020; Odland et al ., 2022; Rakoczy et al ., 2024).”
Jensen, A. A., Cecchi, C. R., Hibicke, M., Bach, A. H., Kaadt, E., Märcher-Rørsted, E., Nichols, C. D., Elfving, B., & Kristensen, J. L. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00208 · Cited by 4
Self-citationModulating Neuroplasticity: Lessons Learned from Antidepressants and Emerging Novel Therapeutics
Yates, C. G., Kruse, J. L., Price, J. B., Robertson, A. A. B., & Tye, S. J. (2021) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-021-00249-9 · Cited by 4
Stanford, S. C. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251360754 · Cited by 4
Psilocybin does not induce the vulnerability marker HSP70 in neurons susceptible to Olney’s lesions
Iorgu, A.-M., Vasilescu, A.-N., Pfeiffer, N., Spanagel, R., Mallien, A. S., Inta, D., & Gass, P. (2023) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-023-01699-3 · Cited by 3
Psilocybin and ketamine affect novel neuropeptides gene expression in the rat hypothalamus
Pałasz, A., Pukowiec, M., Bogus, K., Suszka‐Świtek, A., Filipczyk, Ł., Mordecka‐Chamera, K., Worthington, J. J., Sygidus, M., Wojtas, A., Bysiek, A., et al. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251330783 · Cited by 2
“A reduced anxiety-like behavior in elevated plus maze (EPM) test was also evidenced in rats seven days after exposure to single doses of psylocybin and ketamine (Hibicke et al., 2020).”
Bhat, A., Zolali, E., Sakib, M. A., Rahimian, M., McMahon, L. R., German, N., & Obeng, S. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6c00202 · Cited by 2
King, J. L., Effinger, D. P., Basquez-Pfeifer, C., Wallingford, J. R., Calderon, J. R., O’Connell, C. K., & Thompson, S. M. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-04174-4 · Cited by 2
“LSD also has antidepressant-like actions at comparable doses [26, 27].”
A long trip into the universe: Psychedelics and space travel
Lerer, L. B., & Varia, J. C. (2022) · Frontiers in Space Technologies · doi:10.3389/frspt.2022.899159 · Cited by 2
“There is a growing body of research, mostly from non-human studies indicating that psychedelics enhance neuroplasticity (structural and functional) and have utility in the treatment of psychiatric conditions (Hibicke et al., 2020; Shao et al., 2021; Thomas et al., 2022).”
BackgroundVideira, N. B., Nair, V., Paquet, V., & Calhoun, D. (2023) · Journal of Applied Toxicology · doi:10.1002/jat.4533 · Cited by 2
“Studies in rodents showed that LSD (Buchborn et al., 2014; Hibicke et al., 2020), psilocybin (Hibicke et al., 2020), psilocin (Horsley et al., 2018), and DMT (Cameron et al., 2018; Cameron et al., 2019) correlate long-term beneficial behavioral effects like measures of coping strategy and cognitive…”
BackgroundInfluentialMcGovern, H. T., Wellman, N., Hutchinson, B. T., Oestreich, L., Cooper, S., Fonzo, G. A., & Doss, M. K. (2026) · Psychopharmacology · doi:10.1007/s00213-026-07163-z · Cited by 2
Hibicke, M., Billac, G. B., & Nichols, C. D. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2023.0037 · Cited by 2
“Psychedelics such as the psilocin prodrug psilocybin have been shown to have rapid, persistent antidepressant, and anxiolytic effects in humans from only one or two doses, 1–6 and antidepressant-like effects in rats 7–9 and fruit flies.”
Self-citationPsychiatric Applications of Psychedelics
Tiwari, P., Ehrenkranz, R. C., & Yaden, D. B. (2024) · Advances in Psychiatry and Behavioral Health · doi:10.1016/j.ypsc.2024.04.005 · Cited by 2
Contribution of serotonin 5-HT2A receptor to antidepressant effect of serotonergic psychedelics
Ibi, D. (2023) · Folia Pharmacologica Japonica · doi:10.1254/fpj.22141 · Cited by 2
Psychodeliki - lepsza alternatywa leczenia depresji?
Gołembiowska, K. (2021) · Nauka · doi:10.24425/nauka.2021.137644 · Cited by 2
“Podobny, szybki efekt przeciwdepresyjny i przeciwl ę kowy psylocybiny uzyskano w modelu zwie-rz ę cym z u ż yciem szczurów Wistar Kyoto (WKY), dedykowanych do badania dzia ł ania przeciwdepresyjnego i przeciwl ę kowego (Hibicke et al. 2020).”
BackgroundInfluentialGattuso, J. J., Wilson, C., Hannan, A. J., & Renoir, T. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03005-0 · Cited by 2
“Finally, we commend the research team on investigating grooming behaviour well after the single psilocybin and PME administration (i.e., 7 weeks post-treatment) as previous research has found therapeutic effects of psilocybin lasting up to 41 days [6].”
Jevtić, M. (2025) · Engrami · doi:10.5937/engrami47-57385 · Cited by 1
Sobańska, A. W., Sobański, A. M., & Brzezińska, E. (2026) · Molecules · doi:10.3390/molecules31020212 · Cited by 1
“…that N,N-dimethyltryptamine (DMT) improves mood and reduces anxiety [18] and psychedelics such as LSD or psylocibin have antidepressant effects [19]—with the likely hypothesis that psychedelic tryptamines can induce hallucinogenic and therapeutic effects through activation of the same receptor…”
Wright, R. R., Treadwell, K. R. H., & Hughes, J. L. (2022) · Psi Chi Journal of Psychological Research · doi:10.24839/2325-7342.jn27.3.223 · Cited by 1
Lodetti, G., Réus, G. Z., & Rico, E. P. (2026) · Neuroscience · doi:10.1016/j.neuroscience.2026.01.022 · Cited by 1
Psilocybin restores behavioral and neuroplastic deficits induced by chronic stress in rats
Bysiek, A., Szpręgiel, I., Wojtas, A., Maćkowiak, M., Wawrzczak‐Bargieła, A., Leśkiewicz, M., Trojan, E., Kamińska, K., Kumorek, W., Bilecki, W., et al. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111710 · Cited by 1
Blocking 5-HT2B receptors abolishes psilocybin’s efficacy in the rat forced swim test
Seillier, L., Seillier, A., Zvolska, M. A., & Šlamberová, R. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261458349 · Cited by 1
Younkin, J., Bansode, A. H., Saha, S., Paymode, A., Maltman, J. L., Jones, C. B., Silverman, J. M., Buzzi, B., Jaster, A. M., Fiorillo, M., et al. (2026) · Science Signaling · doi:10.1126/scisignal.adw6055 · Cited by 1
Song, C., Chang, T., Buchborn, T., & Knöpfel, T. (2026) · Nature Communications · doi:10.1038/s41467-026-77238-0 · Cited by 1
“In an apparent disagreement with the body of supportive fi ndings of psilocybin ’ s lasting effects, a recent large-scale multicentre study reported no lasting effects of psilocybin in normal C57BL/6 mice 31 , contradicting several earlier reports 9,11,32,33 .”
Lodetti, G., Redivo, H., Teixeira, A. G., de Farias, A. C. S., Pacagnan, L. D. O., Rohling, J. P. V., Endler, A. T., Zampronio, E. P., de Souza, D. D. P., Assis, V. F., et al. (2026) · Journal of Neural Transmission · doi:10.1007/s00702-026-03287-w · Cited by 1
TOTEs and trauma 2: a rat maternal care and stress epigenetic schematic
Patterson, K. E. (2023) · Kybernetes · doi:10.1108/k-01-2023-0083 · Cited by 1
Mechanisms of enhancer function in neuronal systems in health and disease
Zea-Redondo, L., & Pombo, A. (2022) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2022.100443 · Cited by 1
Sub-Anesthetic Dose of Ketamine Improves Cognitive Function and Motor Responses in Wistar Rats
Uahomo, P. O., Ibubeleye, V. T., Ezerioha, C. E., & Adheke, O. M. (2023) · International Neuropsychiatric Disease Journal · doi:10.9734/indj/2023/v19i4380 · Cited by 1
Ezeaka, U. C., Kim, H. J. J., & Laprairie, R. B. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666230705151922 · Cited by 2
Kelley, D. P., Venable, K. E., Billac, G. B., Destouni, A., Ebenezer, P. J., Stadler, K., Nichols, C. D., Barker, S. A., & Francis, J. (2021) · Research Square · doi:10.21203/rs.3.rs-602961/v1 · Cited by 1
Self-citationKelley, D. P. (2022) · Louisiana State University · doi:10.31390/gradschool_dissertations.5761 · Cited by 1
Therapeutic dissociation: From non-ordinary states to psychological transformationPreprint
Clingo, J. (2024) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/ypr7w · Cited by 1
Zeifman, R. J. (2024) · doi:10.32920/26052859.v1 · Cited by 1
Unmet need in depression: Psilocybin, a breakthrough treatment option
Chahar, Y. K. (2021) · International Journal of Advanced Research in Medicine · doi:10.22271/27069567.2021.v3.i1f.159
“Recent study in rats showed therapeutic efficacy of psilocybin more persistent than that of ketamine ([14]).”
BackgroundChafee, H. (2022) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.19579795
Epigenetic Approaches to Behavioral Neuroscience
Lee, R. S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819641-0.00097-9
Well-Being and the Outdoors: An Environmentalism Study Among a Religious Student Population
Pires-Gifford, L., Hoffmann, S., Arroyo, E., Jones, N., Waite, B., & Wright, R. R. (2022) · Psi Chi Journal of Psychological Research · doi:10.24839/2325-7342.jn27.3.185
Translational research investigating psilocybin: underlying neurobiological mechanisms
van den Berg, M. M. J. (2023) · Research Publications (Maastricht University) · doi:10.26481/dis.20230120mb
Therapeutic Use of Ketamine in Psychiatric Disorders
Jones, J., Morgan, C. J. A., & Malcolm, R. J. (2023) · Frontiers research topics · doi:10.3389/978-2-8325-1050-6
The psychedelic renaissance: can psilocybin possibly combat depression?
Raheel, H., Naeem, U., Shaikh, A., & Shaikh, O. A. (2022) · International Journal of Surgery Global Health · doi:10.1097/gh9.0000000000000089
Ajah, A. A., & Egbono, F. F. (2023) · Saudi Journal of Biomedical Research · doi:10.36348/sjbr.2023.v08i04.001
Ortega, J. E., Meana, J. J., Horrillo, I., Erkizia-Santamaría, I., & Álvarez, N. M. (2023) · I. Ikergazte: Nazioarteko ikerketa euskaraz. Kongresuko artikulu-bilduma · doi:10.26876/ikergazte.v.04.14
SANTOS, R. G. D., & Hallak, J. E. C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18496-3.00015-x
Mattu, J., & Sullivan, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780192898371.003.0007
5-HT2AR and its implication on anti-depression therapy development
Chen, Y. (2024) · Theoretical and Natural Science · doi:10.54254/2753-8818/49/20241282
Metadata
- Authors
- Hibicke, M., Landry, A. N., Kramer, H. M., Talman, Z. K., & Nichols, C. D.
- Affiliations
- Louisiana State University (US)
- Corresponding author
- Nichols, Charles D.
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-03-05
- Volume
- 11
- Issue
- 6
- Pages
- 864-871
- ISSN
- 1948-7193 (ISSN-L)
- OpenAlex
- W3010499243
- Cited by
- 205
- References
- 65
- Citations by year
- 2026: 20 · 2025: 34 · 2024: 38 · 2023: 40 · 2022: 42 · 2021: 20 · 2020: 11
- FWCI
- 11.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- ACS Chemical Neuroscience (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Funders
- Eleusis PBC (NA)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- psilocybin, LSD, ketamine, psychedelics, antidepressant effects, depression, subjective experience, rat model of depression, rapid-acting antidepressants
- MeSH terms
- Animals, Antidepressive Agents, Depression, Hallucinogens, Ketamine, Rodentia, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.